Track record · closed signal

Pfizer Inc. (PFE) — closed signal from August 13, 2025

Partial Published before the outcome was known, scored automatically when the window closed on November 11, 2025 — +3.8% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$23.90 – $24.38Entry zone — fair-value band

$24.58Published — price the day we called it

$27.78Target — the price the thesis aimed for

$27.21Peak — highest point inside the window, not a realized return

$25.51Window close — end-of-window price, context only

What happened

Partial

Reached 71% of the predicted growth at its peak, without hitting the target.

At window close

+3.8%

realized, from the publication price to the last close inside the window

Peak gain

+10.7%

peak, from the publication price — not a realized return

S&P 500, same window

+6.2%

SPY over the identical days, dividend-adjusted

Window close

$25.51

last close inside the window, ended November 11, 2025

Peak price

$27.21

peak on October 3, 2025 — not a realized return

Days to target

—

The thesis — published August 13, 2025

Predicted growth

+15%

over the measurement window

Target price

$27.78

the price the thesis aimed for

Entry zone

$23.90 – $24.38

the fair-value band we waited for

Price at publication

$24.58

published August 13, 2025

Confidence

85%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer's trend looks to be turning up, with more buyers stepping in and price action firming. A new note this week explains why its roughly 7% dividend looks safer: more cash coming in, less debt pressure, and new products launching. In a choppy market, a big healthcare company with improving signs can get revalued higher. Buying near today's range aims for a steady recovery over the next 0-3 months.

Primary drivers

More buyers than usual, and trading activity is heavier than normal
A recent company note says the 7% dividend now looks safer for investors
Recent average price is climbing, showing the trend is healing steadily
Large, steady drug business can help hold value while you collect income

How it played out

PFE: thesis partly played out but target was missed

Lyra published PFE at 24.58 on 2025-08-13 with a short-term recovery thesis. It expected 15% growth and pointed to heavier buying, firmer price action, a roughly 7% dividend that looked safer, less debt pressure, and new products launching. The setup was a steady recovery over the next 0-3 months.

Inside the window, PFE rose to 27.21 on 2025-10-03, a 10.7% peak gain. The target was 27.78, and the stock stayed below it. It ended the window at 25.51 on 2025-11-11. The thesis partly played out, but it did not reach the target.

What happened during the window

On 2025-09-22, Pfizer announced an agreement to acquire Metsera, according to MarketWatch. On 2025-10-31, Axios reported that Pfizer filed a lawsuit seeking to block Novo Nordisk's rival bid for Metsera.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals